Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.

Conference call details:

Date:

November 5, 2026

Time:

8:30 a.m. ET

URL to register phone:

Register Here

Dial-in number:

(+1) 888-880-3330 (U.S.) or (+1) 646-357-8766 (International)

Webcast:

The live webcast can be accessed at ir.novavax.com/events

A replay of the webcast will be available at ir.novavax.com/events and over the phone approximately two hours after the event:

Replay dial-in number:

(+1) 800-770-2030 (U.S.) or (+1) 609-800-9909 (International)

Passcode:

5780712#

About Novavax

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors

Naina Zaman

240-410-5353

[email protected]

Media

Yvonne Sprow

240-720-7804

[email protected]

SOURCE Novavax, Inc.